The U.S. FDA approved two doses of Pfizer Inc.’s medicine Xeljanz for treating active psoriatic arthritis.

Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales despite regulatory concerns about side effects having frustrated the German company’s ambitions almost seven years ago.

Belgium-based reMYND’s pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk.

Teva Pharmaceutical announced a comprehensive restructuring plan that includes the elimination of 25 percent of the company’s global workforce.

Pristine operating theaters and state-of-the-art medical equipment are featured in a new Dubai hospital that opened – exclusively for camels.

Jeremy Perrott, McCann Health Global Chief Creative Officer, created the film that is meant to be a wake-up call that delivers a shocking moment of truth, like a stinging slap across the face. The visual style of filming the teenage boy’s first-person point of view, delivers an immersive and immediate experience that shines a light on the danger of what can happen if parents do not take steps to create a prescription drug safe home.

In today’s world of healthcare advertising and marketing, should agencies do less telling and more listening? The answer is yes, according to new data on how well healthcare marketers think their agencies listen.

The U.S. Food and Drug Administration approved Pfizer Inc.’s second biosimilar to Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade.

2017 has shaped up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.

Revance Therapeutics Inc. will wait to seek partnerships with bigger drugmakers until the company is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.